New Immune-Boosting combo targets Tough-to-Treat skin cancer

NCT ID NCT04303117

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This study is testing whether two drugs that help the immune system fight cancer can help people with advanced Kaposi sarcoma (KS), a type of skin cancer. Up to 80 adults whose KS has been treated before will receive injections of PDS01ADC alone or combined with M7824, given through a vein. The goal is to see if these drugs are safe and can shrink tumors in people who need new treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

KAPOSI SARCOMA